LQDA (Liquidia) Moat Score: 5/10 (As of Jul. 01, 2026)


LQDA Liquidia Corp LQDA
67 GF Score
Price $79.72
GF Value $223.17
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Moat Score?

Liquidia LQDA +6.08% 67 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $223.17 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Liquidia ranks better than 94.67% on this metric.

Liquidia has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Liquidia has Narrow Moat: Liquidia Corp has a solid narrow moat due to its proprietary PRINT technology and valuable patents in drug delivery. However, it faces regulatory challenges and lacks the scale and brand strength for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Liquidia might have Narrow Moat - Solid narrow moat.

Liquidia  (NAS:LQDA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Liquidia Moat Score Related Terms

LQDA vs LNTH, HIMS, AMRX: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liquidia's Moat Score distribution charts can be found below:

* The bar in red indicates where Liquidia's Moat Score falls into.


LQDA
67GF Score
Liquidia Corp LQDA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Liquidia (LQDA) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Liquidia ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Liquidia's Moat Score too high?
Liquidia's current Moat Score is 5. Based on the distribution chart, Liquidia ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Moat Score compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #55 out of 1031 companies for Moat Score. This places Liquidia in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Liquidia's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $223.17, compared to a current price of $79.72 — trading 64.3% below its estimated fair value. The current Moat Score is 5. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Liquidia (LQDA), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $79.72 is trading 64.3% below its estimated GF Value™ of $223.17. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Moat Score: 5
  • GF Value™: $223.17 vs. price of $79.72 (64.3% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.72
Price
$223.17
GF Value